Linked Life Data

19285261

Source:http://linkedlifedata.com/resource/pubmed/id/19285261

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-3-16
pubmed:abstractText
Endogenous cannabinoids (ECs) are ubiquitous lipid signaling molecules provided by a number of central and peripheral effects, which are mediated mainly by the specific receptors CB1 and CB2. In the last decade a considerable number of studies has shown that ECs and their receptors play an important role in the pathophysiology of liver diseases. The EC system is strongly up-regulated during chronic liver diseases. Until now it has been implicated in the pathogenesis of fatty liver disease associated with obesity, alcohol abuse, and hepatitis C, in the progression of fibrosis to cirrhosis, and in the development of portal hypertension, hyperdynamic circulatory syndrome and its complications, and cirrhotic cardiomyopathy. Furthermore, the EC system can participate in the pathogenesis of acute liver injury by modulating the mechanisms responsible for cell injury and inflammatory response. Thus, targeting the CB1 and CB2 receptors represents a potential therapeutic goal for the treatment of liver diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1532-1908
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
65-77
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The role of the endocannabinoid system in liver diseases.
pubmed:affiliation
Department of Clinical Medicine, Center for Applied Biomedical Research (C.R.B.A.), Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. paolo.caraceni@unibo.it
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't